Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

Diabetes Care

Volumn 35, Issue 6, 2012, Pages 1232-1238

  Rosenstock, Julio ^a   Aggarwal, Naresh ^b   Polidori, David ^c   Zhao, Yue ^d   Arbit, Deborah ^d   Usiskin, Keith ^d   Capuano, George ^d   Canovatchel, William ^d  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b Aggarwal and Associates Ltd   (Canada)

^c Janssen Global Services LLC   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SITAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE URINE LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POLLAKISURIA; POLYURIA; SIDE EFFECT; TREATMENT DURATION; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84861781220     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1926     Document Type: Article

References (17)

1. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-453
2. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-1277
3. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43 (Pubitemid 46046470)
4. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-526
5. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-672
6. Bagga A, Bajpai A, Menon S. Approach to renal tubular disorders. Indian J Pediatr 2005;72:771-776 (Pubitemid 41571399)
7. Polidori D, Sha S, Devineni D, Rothenberg P. The renal glucose threshold is increased in patients with type 2 diabetes: results from a novel method for measuring the renal threshold. Late-breaking abstract presented at the 70th Scientific Sessions of the American Diabetes Association, 25-29 June 2010, Orlando, Florida
8. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Effects of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor on vulvovaginal candidal colonization in patients with type 2 diabetes mellitus (T2DM). Late-breaking abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 24-27 June 2011, San Diego, California
9. Polidori D, Zhao Y, Sha S, Canovatchel W. Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes. Late-breaking abstract presented at the 70th Scientific Sessions of the American Diabetes Association, 25-29 June 2010, Orlando, Florida
10. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037-1044 (Pubitemid 18075639)
11. Gumbiner B, Polonsky KS, Beltz WF, et al. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1990;70:1594-1602
12. Geerlings SE, Stolk RP, Camps MJL, Netten PM, Collet TJ, Hoepelman AI; Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000;23:1737-1741
13. Goswami R, Dadhwal V, Tejaswi S, et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 2000;41:162-166
14. US Food & Drug Administration Endocrinologic & Metabolic Advisory Committee. Background document on dapagliflozin (BMS-512148 NDA 202293) [article online], 13 June 2011. Available from http://www.fda.gov/downloads/ Advisory- Committees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262996.pdf. Accessed 4 August 2011
15. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 15 April 2011 [Epub ahead of print]
16. Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant 2010;25:2041-2043
17. Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008;5:e197